McKesson (NYSE:MCK) Announces Q4 CY2025 Results Meeting Projections

McKesson (MCK) Q4 CY2025 Earnings Overview

McKesson, a leading distributor and service provider in the healthcare sector, reported fourth-quarter results for calendar year 2025 that matched Wall Street’s revenue projections. The company achieved $106.2 billion in sales, reflecting an 11.4% increase compared to the previous year. Adjusted earnings per share reached $9.34, slightly surpassing analyst expectations by 0.7%.

Curious if McKesson is a smart investment right now?

Highlights from the Quarter

• Total Revenue: $106.2 billion, matching analyst forecasts and up 11.4% year-over-year
• Adjusted Earnings Per Share: $9.34, beating estimates of $9.27 by 0.7%
• Full-Year EPS Guidance: Management raised the midpoint to $39, a 1% increase
• Operating Margin: 1.5%, consistent with the same period last year
• Free Cash Flow: $1.06 billion, a significant turnaround from -$2.58 billion a year ago
• Market Value: $105.1 billion

About McKesson

Founded in 1833, McKesson stands as one of the oldest continuously operating companies in the United States. The company specializes in distributing pharmaceuticals and medical supplies, as well as offering technology solutions to pharmacies, hospitals, and other healthcare organizations.

Revenue Performance

Consistent long-term growth is a hallmark of a high-quality business. Over the past five years, McKesson’s revenue has grown at a compounded annual rate of 10.9%, slightly outpacing the average for healthcare companies and demonstrating strong demand for its products and services.

While we value long-term growth, recent trends can reveal shifts in the industry. In the last two years, McKesson’s annualized revenue growth accelerated to 14.9%, outstripping its five-year average and indicating rising demand.

Focusing on its core U.S. Pharmaceutical division, this segment has achieved an average annual growth rate of 13.6% over the past two years.

For the latest quarter, McKesson’s revenue rose 11.4% year-over-year, aligning with market expectations at $106.2 billion.

Looking forward, analysts anticipate revenue growth of 9.8% over the next year, which is a slowdown compared to recent years. Nonetheless, given McKesson’s scale, this outlook remains positive and suggests continued confidence in its offerings.

Industry Trends

Technology continues to transform every sector, including healthcare. The demand for software tools that support developers—whether for cloud infrastructure, media integration, or content delivery—remains strong.

Profitability and Margins

Operating Margin

Operating margin is a key indicator of profitability, reflecting how much profit remains after covering core expenses such as marketing and research. Over the past five years, McKesson’s operating margin has averaged 1.3%, which is relatively low for the healthcare industry and points to a less-than-ideal cost structure.

Despite some fluctuations, the operating margin has remained stable, suggesting that revenue growth has not yet translated into improved cost efficiency or economies of scale.

In the fourth quarter, McKesson’s operating margin stood at 1.5%, unchanged from the same period last year, indicating a steady cost base.

Earnings Per Share (EPS)

While revenue growth shows how a company is expanding, the change in earnings per share (EPS) reveals how profitable that growth is. Over the last five years, McKesson’s EPS has grown at a robust 18% compounded annual rate, outpacing its revenue growth and indicating improved profitability per share.

A closer look reveals that McKesson has reduced its share count by 22.4% over five years through stock buybacks, which has contributed to the strong EPS growth. This means the increase in EPS is partly due to financial strategies rather than solely operational improvements.

For the recent quarter, adjusted EPS reached $9.34, up from $8.03 a year earlier and close to analyst projections. Wall Street expects full-year EPS to climb 14.2% to $37.58 over the next 12 months.

Final Thoughts on McKesson’s Q4 Results

McKesson’s slight beat on full-year EPS guidance was a positive sign, and the market responded with a 2.1% increase in the stock price to $839 following the announcement. While this quarter’s results are encouraging, they represent just one part of the company’s overall story. Assessing long-term quality and valuation together is essential when considering an investment.

Want a deeper dive into McKesson’s prospects?